Using a preclinical model of colorectal cancer (cecum-based orthotopic transplantation), the authors observed that intravenous injections of miR-424 led to the downregulation of tumor-secreted vesicles, which improved response compared with combined anti-PD-1 and anti-CTLA-4 therapy [36]. This evidence concerns the gene CTLA4 and neoplasm.